Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Fasinumab vs Placebo and Naproxen in Osteoarthritis Pain of the Knee or Hip
2016-005020-29Phase 3Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Aug 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fasinumab in knee osteoarthritis (OA), hip osteoarthritis and osteoarthritis (OA) (5 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Primary WOMAC pain change. Started Aug 2017; status: completed.
02
Drugs
fasinumab
03
Conditions
knee osteoarthritis (OA)hip osteoarthritisosteoarthritis (OA)
Beyond the preview
Go deeper on 2016-005020-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-005020-29.